News
PHIO
4.717
+3.66%
0.167
Weekly Report: what happened at PHIO last week (0708-0712)?
Weekly Report · 3d ago
Phio Pharmaceuticals Announces Exercise Of Warrants For $3.1M Gross Proceeds
Phio Pharmaceuticals Corp. Has entered into definitive agreements to exercise certain outstanding warrants to purchase up to 545,286 shares of common stock. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.1 million. The company's proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells.
Benzinga · 6d ago
Weekly Report: what happened at PHIO last week (0701-0705)?
Weekly Report · 07/08 10:07
BUZZ-U.S. STOCKS ON THE MOVE-Golar LNG, gold miners, Big Tech
Dow and S&P 500 struggle for direction after mixed payrolls data. Golar LNG up 6.5% on 20-year deal in Argentina. Apple up 1.7% after report of strong sales in second quarter. Gold miners rise as gold prices rise. Big Tech stocks rise.
Reuters · 07/05 16:14
BUZZ-Phio Pharma falls on ending share purchase agreement with Triton Funds
Shares of biotech co Phio Pharmaceuticals fall 8.8% to $4.77. Company terminated share purchase agreement with Triton Funds LP on July 3. Co could have purchased up to 18.8 per cent of co's stock. Co's stock down 91.5 per cent YTD.
Reuters · 07/05 13:57
Phio Pharmaceuticals Scraps Share Sale to Triton Funds
TipRanks · 07/05 12:45
Phio Pharmaceuticals terminates share purchase agreement with Triton Funds
Healthcare Phio Pharmaceuticals terminates share purchase agreement with Triton Funds LP. The company has terminated its agreement to purchase up to 18.8% of the company's common stock. Phio pharmaceuticals Corp. (PHIO) stock is down 2.7% in the last week.
Seeking Alpha · 07/05 12:38
PHIO PHARMACEUTICALS CORP - TERMINATES SHARE PURCHASE AGREEMENT WITH TRITON
Reuters · 07/05 12:02
PHIO PHARMACEUTICALS CORP -DEAL AFFORDED TRITON OPPORTUNITY TO PURCHASE UP TO 18.8% OF CO’S COMMON STOCK
Reuters · 07/05 12:02
PHIO PHARMACEUTICALS CORP - HAS APPROVED A REVERSE STOCK SPLIT OF ITS SHARES OF COMMON STOCK AT A RATIO OF 1-FOR-9
Reuters · 07/02 21:02
PHIO PHARMACEUTICALS - REVERSE STOCK SPLIT IS BEING IMPLEMENTED TO COMPLY WITH MINIMUM BID PRICE REQUIREMENT FOR CONTINUED LISTING ON NASDAQ
Reuters · 07/02 21:02
Weekly Report: what happened at PHIO last week (0624-0628)?
Weekly Report · 07/01 10:07
Weekly Report: what happened at PHIO last week (0617-0621)?
Weekly Report · 06/24 10:10
Phio Pharmaceuticals Shareholders Approve Key Proposals
TipRanks · 06/21 23:01
Weekly Report: what happened at PHIO last week (0610-0614)?
Weekly Report · 06/17 10:06
Phio Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern about a company's prospects. CarParts.com, Inc. And FlexShopper are recent notable insider transactions for penny stocks. The Dow Jones index closed lower by more than 100 points on Tuesday.
Benzinga · 06/12 11:07
Sypris Solutions And 3 Other Stocks Under $2 Insiders Are Buying
Dow Jones index closed higher by around 0.2% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Insider transactions for penny stocks are a good indicator of a company's future prospects. PodcastOne, Inc. And Phio Pharmaceuticals Corp. Have had recent notable insider transactions.
Benzinga · 06/11 11:27
Weekly Report: what happened at PHIO last week (0603-0607)?
Weekly Report · 06/10 10:07
Weekly Report: what happened at PHIO last week (0527-0531)?
Weekly Report · 06/03 10:09
PHIO PHARMACEUTICALS ANNOUNCES POSITIVE RECOMMENDATION FROM SAFETY MONITORING COMMITTEE OF PHASE 1B CLINICAL STUDY OF PHIO S LEAD COMPOUND PH-762
Reuters · 05/28 21:02
More
Webull provides a variety of real-time PHIO stock news. You can receive the latest news about Phio Pharmaceuticals Corp through multiple platforms. This information may help you make smarter investment decisions.
About PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.